EMEA-002152-PIP01-17
Key facts
| Invented name |
Darzalex
|
| Active substance |
Daratumumab
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0180/2018
|
| PIP number |
EMEA-002152-PIP01-17
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of lymphoid malignancies (except mature B-cell neoplasms)
|
| Route(s) of administration |
|
| Contact for public enquiries |
Janssen-Cilag International N.V.
E-mail: nbuhl@its.jnj.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|